Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)
Evofem Reports Fifth Consecutive Year of Net Sales Growth
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women's Health at Fierce JPM Week 2026
Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store
Financial Contrast: Evofem Biosciences (NASDAQ:EVFM) and BetterLife Pharma (OTCMKTS:PVOTF)
Evofem Biosciences (NASDAQ:EVFM) Stock Passes Above 50 Day Moving Average – What’s Next?
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey
Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
Evofem Biosciences Honors World Contraception Day
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
Evofem Biosciences to Present at Emerging Growth Conference
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
Why Is Evofem (EVFM) Stock Up 85% Today?
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
Evofem to Participate in the Virtual Investor Ask the CEO Conference
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire